Bioventus (NASDAQ:BVS) Sets New 52-Week High – Time to Buy?

Bioventus Inc. (NASDAQ:BVS) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $11.81 and last traded at $11.7430, with a volume of 320222 shares trading hands. The stock had previously closed at $10.48.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BVS shares. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Barrington Research reissued an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research report on Tuesday, June 30th. Finally, CJS Securities began coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Bioventus presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Bioventus Trading Down 2.5%

The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The company has a market capitalization of $959.87 million, a price-to-earnings ratio of 28.02, a P/E/G ratio of 1.52 and a beta of 0.65. The business’s 50-day moving average price is $9.60 and its two-hundred day moving average price is $8.89.

Bioventus (NASDAQ:BVS) last released its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Research analysts predict that Bioventus Inc. will post 0.77 earnings per share for the current year.

Hedge Funds Weigh In On Bioventus

Several hedge funds have recently bought and sold shares of BVS. Wesbanco Bank Inc. acquired a new stake in shares of Bioventus in the 1st quarter valued at $895,000. Legato Capital Management LLC lifted its position in shares of Bioventus by 1,042.8% during the 4th quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock worth $1,023,000 after buying an additional 125,525 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Bioventus in the fourth quarter valued at about $2,008,000. Inspire Investing LLC bought a new position in Bioventus in the first quarter valued at about $1,670,000. Finally, Anderson Financial Strategies LLC grew its position in Bioventus by 58.3% in the fourth quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock valued at $1,586,000 after acquiring an additional 78,488 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.